13D Filings
ENZON PHARMACEUTICALS INC
ENZN
Amendment
Ownership

48.60%

Total Shares

36,056,636

Issuer CIK

727510

CUSIP

293904108

Event Date

Dec 18, 2024

Accepted

Dec 19, 2024, 04:30 PM

Reporting Persons (10)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
BECKTON CORP
CO
48.60%36,056,636036,056,636
IPH GP LLC
Other
48.60%36,056,636036,056,636
ICAHN ENTERPRISES HOLDINGS L.P.
Partnership
48.60%36,056,636036,056,636
ICAHN ENTERPRISES G.P. INC.
CO
48.60%36,056,636036,056,636
CARL C ICAHN
Individual
48.60%36,056,636036,056,636
Icahn Capital LP
Partnership
48.60%36,056,636036,056,636
Icahn Partners LP
Partnership
28.50%21,132,72521,132,7250
Icahn Onshore LP
Partnership
28.50%21,132,725021,132,725
ICAHN PARTNERS MASTER FUND LP
Partnership
20.10%14,923,91114,923,9110
Icahn Offshore LP
Partnership
20.10%14,923,911014,923,911
Disclosure Items (2)

Security Title

Common Stock, No par value

Issuer Name

ENZON PHARMACEUTICALS INC

Item 4 of the Original 13D is hereby amended and supplemented as follows: The Reporting Persons beneficially own an aggregate of approximately 49% of the outstanding Shares, as well as an aggregate of approximately 98% of the outstanding Series C Preferred Stock of the Issuer. The Reporting Persons and Viskase Companies, Inc. ("Viskase"), of which the Reporting Persons beneficially own an aggregate of approximately 91% of the total outstanding shares of common stock, have discussed and are currently considering a potential business combination transaction involving Viskase and the Issuer through a negotiated merger transaction or otherwise (a "Potential Transaction"). The Board of Directors of Viskase has established a special committee of the Board of Directors of Viskase (the "Viskase Special Committee") consisting of directors independent of the Reporting Persons to consider, evaluate and negotiate a Potential Transaction on behalf of Viskase. The Viskase Special Committee is empowered to engage, and has engaged, independent financial and legal advisors with respect to a Potential Transaction. On December 19, 2024, a member of the Viskase Special Committee contacted a member of the Board of Directors of the Issuer to explore interest in a Potential Transaction and to indicate that Viskase may formulate and submit a proposal with respect to a potential structure and terms for a Potential Transaction. The Viskase Special Committee member further indicated that it is the Viskase Special Committee's expectation that a special committee of independent directors of the Issuer will be established to consider Viskase's proposal and such other terms of the Potential Transaction as may be considered and negotiated in the future. In connection therewith, the Reporting Persons, Viskase, their affiliates and their respective representatives may engage in other activities, discussions and/or negotiations regarding a Potential Transaction. The Reporting Persons do not intend to update additional disclosures regarding a Potential Transaction until a definitive agreement has been reached, or, if applicable, they determine definitively that a Potential Transaction will not proceed, and/or unless disclosure is otherwise required under applicable U.S. securities laws. Discussions, negotiations and consummation of a Potential Transaction may result in one or more of the transactions, events or actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, including, without limitation, an acquisition of additional securities of the Issuer, an extraordinary corporate transaction (such as a merger) involving the Issuer, delisting of the Shares from the Nasdaq exchange and other material changes in the Issuer's business or corporate structure. No assurances can be given that a definitive agreement will be reached or that a Potential Transaction will be consummated. The Reporting Persons and its subsidiaries reserve the right to modify or withdraw any Potential Transaction at any time. The Reporting Persons and its subsidiaries reserve the right to formulate other plans or make other proposals which could result in one or more of the transactions, events or actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, and to modify or withdraw any such plan or proposal at any time.

ENZON PHARMACEUTICALS INC — Schedule 13D | 13D Filings